You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameRotigotine
Accession NumberDB05271
TypeSmall Molecule
GroupsApproved
DescriptionRotigotine (Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS) in Europe and the United States. It is formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug over the course of 24 hours. Like other dopamine agonists, rotigotine has been shown to possess antidepressant effects and may be useful in the treatment of depression as well. Rotigotine was developed by Aderis Pharmaceuticals. In 1998, Aderis licensed worldwide development and commercialization rights for rotigotine to the German pharmaceutical company Schwarz Pharma (today a subsidiary of the Belgian company UCB S.A.). The drug has been approved by the EMEA for use in Europe in 2006 and is today being sold in several European countries. In 2007, the Neupro patch was approved by the Food and Drug Administration (FDA) as the first transdermal treatment of Parkinson's disease in the United States. However, as of 2008, Schwarz Pharma has recalled all Neupro patches in the United States and some in Europe because of problems with the delivery mechanism. Rotigotine has been authorized as a treatment for RLS since August 2008.
Structure
Thumb
Synonyms
(6S)-6-(propyl(2-(2-thienyl)ethyl)amino)-5,6,7,8-tetrahydro-1-naphthalenol
External Identifiers
  • N-0923
  • SPM 962
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NeuproPatch, extended release2 mg/24hTransdermalUCB, Inc.2012-04-02Not applicableUs
NeuproPatch1 mgTransdermalUcb Canada Inc2013-12-19Not applicableCanada
NeuproPatch, extended release8 mg/24hTransdermalUCB, Inc.2012-04-02Not applicableUs
NeuproPatch6 mgTransdermalUcb Canada Inc2013-06-27Not applicableCanada
NeuproPatch, extended release3 mg/24hTransdermalUCB, Inc.2012-04-02Not applicableUs
NeuproPatch2 mgTransdermalUcb Canada Inc2013-06-27Not applicableCanada
NeuproKitUCB, Inc.2012-04-02Not applicableUs
NeuproPatch8 mgTransdermalUcb Canada Inc2013-06-27Not applicableCanada
NeuproPatch, extended release4 mg/24hTransdermalUCB, Inc.2012-04-02Not applicableUs
NeuproPatch3 mgTransdermalUcb Canada Inc2013-12-19Not applicableCanada
NeuproPatch, extended release1 mg/24hTransdermalUCB, Inc.2012-04-02Not applicableUs
NeuproPatch, extended release6 mg/24hTransdermalUCB, Inc.2012-04-02Not applicableUs
NeuproPatch4 mgTransdermalUcb Canada Inc2013-06-27Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Rotigotine hydrochloride
125572-93-2
Thumb
  • InChI Key: CEXBONHIOKGWNU-NTISSMGPSA-N
  • Monoisotopic Mass: 351.142362856
  • Average Mass: 351.934
DBSALT000155
Categories
UNII87T4T8BO2E
CAS number99755-59-6
WeightAverage: 315.48
Monoisotopic: 315.165685603
Chemical FormulaC19H25NOS
InChI KeyKFQYTPMOWPVWEJ-INIZCTEOSA-N
InChI
InChI=1S/C19H25NOS/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21/h3-7,13,16,21H,2,8-12,14H2,1H3/t16-/m0/s1
IUPAC Name
(6S)-6-{propyl[2-(thiophen-2-yl)ethyl]amino}-5,6,7,8-tetrahydronaphthalen-1-ol
SMILES
CCCN(CCC1=CC=CS1)[[email protected]]1CCC2=C(O)C=CC=C2C1
Pharmacology
IndicationFor use/treatment in neurologic disorders and parkinson's disease as well as moderate-to-severe primary Restless Legs Syndrome.
Structured Indications
PharmacodynamicsRotigotine is an agonist at all 5 dopamine receptor subtypes (D1-D5) but binds to the D3 receptor with the highest affinity. It is also an antagonist at α-2-adrenergic receptors and an agonist at the 5HT1A receptors. Rotigotine also inhibits dopamine uptake and prolactin secretion. There is no indication of a QT/QTc prolonging effect of Neupro in doses up to 24 mg/24 hours. The effects of Neupro at doses up to 24 mg/24 hours (supratherapeutic doses) on the QT/QTc interval was evaluated in a double-blind, randomized, placebo- and positive-controlled (moxifloxacin 400 mg IV, single dose) parallel-group trial with an overall treatment period of 52 days in male and female patients with advanced-stage Parkinson's disease. Assay sensitivity was confirmed by significant QTc prolongation by moxifloxacin.
Mechanism of actionRotigotine, a member of the dopamine agonist class of drugs, is delivered continuously through the skin (transdermal) using a silicone-based patch that is replaced every 24 hours. A dopamine agonist works by activating dopamine receptors in the body, mimicking the effect of the neurotransmitter dopamine. The precise mechanism of action of rotigotine as a treatment for Restless Legs Syndrome is unknown but is thought to be related to its ability to stimulate dopamine
TargetKindPharmacological actionActionsOrganismUniProt ID
D(3) dopamine receptorProteinyes
agonist
HumanP35462 details
D(4) dopamine receptorProteinyes
agonist
HumanP21917 details
D(2) dopamine receptorProteinyes
agonist
HumanP14416 details
D(1B) dopamine receptorProteinunknown
agonist
HumanP21918 details
D(1A) dopamine receptorProteinunknown
agonist
HumanP21728 details
5-hydroxytryptamine receptor 1AProteinunknown
agonist
HumanP08908 details
Alpha-2B adrenergic receptorProteinunknown
antagonist
HumanP18089 details
Related Articles
AbsorptionBioavailability varies depending on the application site. Differences in bioavailability were very small between the abdomen and hip (<1%). In contrast, the shoulder and thigh had a very large different in measured bioavailability (46%), with the shoulder showing the higher value. Tmax, 8 mg dose = 15 - 18 hours (it take approximately 3 hours until rotigotine reaches detectable levels in the plasma). The peak concentration cannot be observered. Steady state is reached in 2-3 days.
Volume of distribution

The weight normalized apparent volume of distribution, (Vd/F), in humans is approximately 84 L/kg after repeated dose administration.

Protein binding92% in vitro and 89.5% in vivo.
Metabolism

Hepatic (CYP-mediated). Rotigotine is extensively and rapidly metabolized by conjugation and N-dealkylation. After intravenous dosing the predominant metabolites in human plasma are sulfate conjugates of rotigotine, glucuronide conjugates of rotigotine, sulfate conjugates of the N-despropyl-rotigotine and conjugates of N-desthienylethyl-rotigotine. Multiple CYP isoenzymes, sulfotransferases and two UDP-glucuronosyltransferases catalyze the metabolism of rotigotine.

SubstrateEnzymesProduct
Rotigotine
Not Available
N-despropyl-rotigotineDetails
Rotigotine
Not Available
N-desthienylethyl-rotigotineDetails
Route of eliminationUrine (71%), Fecal (23%). Most of rotigotine that is excreted in the urine is in the form of inactive conjugates. Unchanged drug made up less <1%.
Half lifeAfter removal of the patch, plasma levels decreased with a terminal half-life of 5 to 7 hours. The pharmacokinetic profile showed a biphasic elimination with an initial half-life of 3 hours.
ClearanceNot Available
ToxicityThe most likely symptoms of overdose would be those related to the pharmacodynamic profile of a dopamine agonist, including nausea, vomiting, hypotension, involuntary movements, hallucinations, confusion, convulsions, and other signs of excessive dopaminergic stimulation.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 Tetrafluoroethane1,1,1,2 Tetrafluoroethane may increase the sedative activities of Rotigotine.Investigational
7-Nitroindazole7-Nitroindazole may increase the sedative activities of Rotigotine.Experimental
AbirateroneThe serum concentration of Rotigotine can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Rotigotine.Approved
AcepromazineAcepromazine may increase the sedative activities of Rotigotine.Approved, Vet Approved
AceprometazineAceprometazine may increase the sedative activities of Rotigotine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Rotigotine is combined with Acetazolamide.Approved, Vet Approved
adipiplonadipiplon may increase the sedative activities of Rotigotine.Investigational
AgomelatineAgomelatine may increase the sedative activities of Rotigotine.Approved, Investigational
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Rotigotine.Approved
AlfaxaloneAlfaxalone may increase the sedative activities of Rotigotine.Vet Approved
AlfentanilAlfentanil may increase the sedative activities of Rotigotine.Approved, Illicit
AliskirenThe risk or severity of adverse effects can be increased when Aliskiren is combined with Rotigotine.Approved, Investigational
AlphacetylmethadolAlphacetylmethadol may increase the sedative activities of Rotigotine.Experimental, Illicit
AlprazolamAlprazolam may increase the sedative activities of Rotigotine.Approved, Illicit, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Rotigotine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Rotigotine.Approved
AmiodaroneThe metabolism of Rotigotine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe therapeutic efficacy of Amisulpride can be decreased when used in combination with Rotigotine.Approved, Investigational
AmitriptylineAmitriptyline may increase the sedative activities of Rotigotine.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Rotigotine.Approved
AmobarbitalAmobarbital may increase the sedative activities of Rotigotine.Approved, Illicit
AmoxapineAmoxapine may increase the sedative activities of Rotigotine.Approved
AmperozideAmperozide may increase the sedative activities of Rotigotine.Experimental
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Rotigotine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Rotigotine.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Rotigotine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Rotigotine.Approved
AprepitantThe serum concentration of Rotigotine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the sedative activities of Rotigotine.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Rotigotine.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Rotigotine.Approved, Investigational
ArtemetherThe metabolism of Rotigotine can be decreased when combined with Artemether.Approved
ArticaineArticaine may increase the sedative activities of Rotigotine.Approved
AsenapineAsenapine may increase the sedative activities of Rotigotine.Approved
AtazanavirThe metabolism of Rotigotine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Rotigotine.Approved
AtomoxetineThe metabolism of Rotigotine can be decreased when combined with Atomoxetine.Approved
AzaperoneAzaperone may increase the sedative activities of Rotigotine.Vet Approved
AzelastineAzelastine may increase the sedative activities of Rotigotine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Rotigotine.Approved
AzithromycinThe metabolism of Rotigotine can be decreased when combined with Azithromycin.Approved
BaclofenBaclofen may increase the sedative activities of Rotigotine.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Rotigotine.Experimental
BarbitalBarbital may increase the sedative activities of Rotigotine.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Rotigotine.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Rotigotine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Rotigotine.Approved
BenperidolBenperidol may increase the sedative activities of Rotigotine.Investigational
BenzocaineBenzocaine may increase the sedative activities of Rotigotine.Approved
Benzyl alcoholBenzyl alcohol may increase the sedative activities of Rotigotine.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Rotigotine.Approved, Withdrawn
BetaxololThe metabolism of Rotigotine can be decreased when combined with Betaxolol.Approved
BexaroteneThe serum concentration of Rotigotine can be decreased when it is combined with Bexarotene.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Rotigotine.Approved
BlonanserinThe therapeutic efficacy of Rotigotine can be decreased when used in combination with Blonanserin.Approved
BoceprevirThe metabolism of Rotigotine can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Rotigotine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Rotigotine can be decreased when it is combined with Bosentan.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Rotigotine.Approved
BrexpiprazoleBrexpiprazole may increase the sedative activities of Rotigotine.Approved
BrimonidineBrimonidine may increase the sedative activities of Rotigotine.Approved
BromazepamBromazepam may increase the sedative activities of Rotigotine.Approved, Illicit
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Rotigotine.Approved, Investigational
BrompheniramineBrompheniramine may increase the sedative activities of Rotigotine.Approved
BrotizolamBrotizolam may increase the sedative activities of Rotigotine.Approved, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Rotigotine.Approved
BupivacaineBupivacaine may increase the sedative activities of Rotigotine.Approved, Investigational
BuprenorphineBuprenorphine may increase the sedative activities of Rotigotine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Rotigotine is combined with Bupropion.Approved
BuspironeBuspirone may increase the sedative activities of Rotigotine.Approved, Investigational
ButabarbitalButabarbital may increase the sedative activities of Rotigotine.Approved, Illicit
ButacaineButacaine may increase the sedative activities of Rotigotine.Vet Approved
ButalbitalButalbital may increase the sedative activities of Rotigotine.Approved, Illicit
ButambenButamben may increase the sedative activities of Rotigotine.Approved
ButethalButethal may increase the sedative activities of Rotigotine.Approved, Illicit
ButorphanolButorphanol may increase the sedative activities of Rotigotine.Approved, Illicit, Vet Approved
CaffeineThe metabolism of Rotigotine can be decreased when combined with Caffeine.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Rotigotine.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Rotigotine.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Rotigotine.Approved
CarbamazepineCarbamazepine may increase the sedative activities of Rotigotine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Rotigotine.Approved
CarbinoxamineCarbinoxamine may increase the sedative activities of Rotigotine.Approved
CarfentanilCarfentanil may increase the sedative activities of Rotigotine.Illicit, Vet Approved
CariprazineThe therapeutic efficacy of Rotigotine can be decreased when used in combination with Cariprazine.Approved
CarisoprodolCarisoprodol may increase the sedative activities of Rotigotine.Approved
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Rotigotine.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Rotigotine.Approved, Investigational
CelecoxibThe metabolism of Rotigotine can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Rotigotine can be increased when it is combined with Ceritinib.Approved
CetirizineCetirizine may increase the sedative activities of Rotigotine.Approved
Chloral hydrateChloral hydrate may increase the sedative activities of Rotigotine.Approved, Illicit, Vet Approved
ChlordiazepoxideChlordiazepoxide may increase the sedative activities of Rotigotine.Approved, Illicit
ChlormezanoneChlormezanone may increase the sedative activities of Rotigotine.Approved, Withdrawn
ChloroprocaineChloroprocaine may increase the sedative activities of Rotigotine.Approved
ChloroquineThe metabolism of Rotigotine can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Rotigotine.Approved, Vet Approved
ChlorphenamineChlorphenamine may increase the sedative activities of Rotigotine.Approved
ChlorpromazineChlorpromazine may increase the sedative activities of Rotigotine.Approved, Vet Approved
ChlorprothixeneChlorprothixene may increase the sedative activities of Rotigotine.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Rotigotine.Approved
ChlorzoxazoneChlorzoxazone may increase the sedative activities of Rotigotine.Approved
CholecalciferolThe metabolism of Rotigotine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Rotigotine.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Rotigotine.Approved
CimetidineThe metabolism of Rotigotine can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Rotigotine can be decreased when combined with Cinacalcet.Approved
CinchocaineCinchocaine may increase the sedative activities of Rotigotine.Approved, Vet Approved
CitalopramThe metabolism of Rotigotine can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Rotigotine can be decreased when combined with Clarithromycin.Approved
ClemastineClemastine may increase the sedative activities of Rotigotine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Rotigotine.Approved
ClidiniumClidinium may increase the sedative activities of Rotigotine.Approved
ClobazamClobazam may increase the sedative activities of Rotigotine.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Rotigotine.Approved, Investigational
clomethiazoleclomethiazole may increase the sedative activities of Rotigotine.Investigational
ClomipramineClomipramine may increase the sedative activities of Rotigotine.Approved, Vet Approved
ClonazepamClonazepam may increase the sedative activities of Rotigotine.Approved, Illicit
ClonidineClonidine may increase the sedative activities of Rotigotine.Approved
ClorazepateClorazepate may increase the sedative activities of Rotigotine.Approved, Illicit
ClotrimazoleThe metabolism of Rotigotine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the sedative activities of Rotigotine.Approved
CobicistatThe serum concentration of Rotigotine can be increased when it is combined with Cobicistat.Approved
CocaineCocaine may increase the sedative activities of Rotigotine.Approved, Illicit
CodeineCodeine may increase the sedative activities of Rotigotine.Approved, Illicit
ConivaptanThe serum concentration of Rotigotine can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Rotigotine can be decreased when combined with Crizotinib.Approved
CyclizineCyclizine may increase the sedative activities of Rotigotine.Approved
CyclobenzaprineCyclobenzaprine may increase the sedative activities of Rotigotine.Approved
CyclosporineThe metabolism of Rotigotine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineCyproheptadine may increase the sedative activities of Rotigotine.Approved
Cyproterone acetateThe serum concentration of Rotigotine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Rotigotine can be decreased when it is combined with Dabrafenib.Approved
DantroleneDantrolene may increase the sedative activities of Rotigotine.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Rotigotine.Approved
DapiprazoleDapiprazole may increase the sedative activities of Rotigotine.Approved
DarifenacinThe metabolism of Rotigotine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Rotigotine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Rotigotine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Rotigotine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Rotigotine can be decreased when combined with Delavirdine.Approved
deramciclanederamciclane may increase the sedative activities of Rotigotine.Investigational
DesfluraneDesflurane may increase the sedative activities of Rotigotine.Approved
DesipramineDesipramine may increase the sedative activities of Rotigotine.Approved
DesloratadineDesloratadine may increase the sedative activities of Rotigotine.Approved, Investigational
DetomidineDetomidine may increase the sedative activities of Rotigotine.Vet Approved
DexamethasoneThe serum concentration of Rotigotine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineDexbrompheniramine may increase the sedative activities of Rotigotine.Approved
DexmedetomidineDexmedetomidine may increase the sedative activities of Rotigotine.Approved, Vet Approved
DextromoramideDextromoramide may increase the sedative activities of Rotigotine.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the sedative activities of Rotigotine.Approved, Illicit, Withdrawn
DezocineDezocine may increase the sedative activities of Rotigotine.Approved
DiazepamDiazepam may increase the sedative activities of Rotigotine.Approved, Illicit, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Rotigotine.Approved
DifenoxinDifenoxin may increase the sedative activities of Rotigotine.Approved, Illicit
DihydrocodeineDihydrocodeine may increase the sedative activities of Rotigotine.Approved, Illicit
DihydroergotamineThe metabolism of Rotigotine can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineDihydroetorphine may increase the sedative activities of Rotigotine.Experimental, Illicit
DihydromorphineDihydromorphine may increase the sedative activities of Rotigotine.Experimental, Illicit
DiltiazemThe metabolism of Rotigotine can be decreased when combined with Diltiazem.Approved
DimenhydrinateDimenhydrinate may increase the sedative activities of Rotigotine.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Rotigotine.Approved
DiphenhydramineDiphenhydramine may increase the sedative activities of Rotigotine.Approved
DiphenoxylateDiphenoxylate may increase the sedative activities of Rotigotine.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Rotigotine.Approved
DoramectinDoramectin may increase the sedative activities of Rotigotine.Vet Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Rotigotine.Approved
DoxepinDoxepin may increase the sedative activities of Rotigotine.Approved
DoxycyclineThe metabolism of Rotigotine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the sedative activities of Rotigotine.Approved, Vet Approved
DPDPEDPDPE may increase the sedative activities of Rotigotine.Investigational
DronedaroneThe metabolism of Rotigotine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the sedative activities of Rotigotine.Approved, Vet Approved
DrotebanolDrotebanol may increase the sedative activities of Rotigotine.Experimental, Illicit
DuloxetineRotigotine may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineDyclonine may increase the sedative activities of Rotigotine.Approved
EcgonineEcgonine may increase the sedative activities of Rotigotine.Experimental, Illicit
ECGONINE METHYL ESTERECGONINE METHYL ESTER may increase the sedative activities of Rotigotine.Experimental
EcopipamEcopipam may increase the sedative activities of Rotigotine.Investigational
EfavirenzEfavirenz may increase the sedative activities of Rotigotine.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Rotigotine.Approved
EliglustatThe metabolism of Rotigotine can be decreased when combined with Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Rotigotine.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Rotigotine.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Rotigotine.Approved
EnfluraneEnflurane may increase the sedative activities of Rotigotine.Approved, Vet Approved
EntacaponeEntacapone may increase the sedative activities of Rotigotine.Approved, Investigational
EnzalutamideThe serum concentration of Rotigotine can be decreased when it is combined with Enzalutamide.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Rotigotine.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Rotigotine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Rotigotine.Approved
ErythromycinThe metabolism of Rotigotine can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Rotigotine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Rotigotine.Approved
EstazolamEstazolam may increase the sedative activities of Rotigotine.Approved, Illicit
EszopicloneEszopiclone may increase the sedative activities of Rotigotine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Rotigotine.Approved
EthanolEthanol may increase the sedative activities of Rotigotine.Approved
EthchlorvynolEthchlorvynol may increase the sedative activities of Rotigotine.Approved, Illicit, Withdrawn
EthosuximideEthosuximide may increase the sedative activities of Rotigotine.Approved
EthotoinEthotoin may increase the sedative activities of Rotigotine.Approved
Ethyl carbamateEthyl carbamate may increase the sedative activities of Rotigotine.Withdrawn
Ethyl loflazepateEthyl loflazepate may increase the sedative activities of Rotigotine.Approved, Illicit
EthylmorphineEthylmorphine may increase the sedative activities of Rotigotine.Approved, Illicit
EtidocaineEtidocaine may increase the sedative activities of Rotigotine.Approved
EtifoxineEtifoxine may increase the sedative activities of Rotigotine.Withdrawn
EtizolamEtizolam may increase the sedative activities of Rotigotine.Approved
EtomidateEtomidate may increase the sedative activities of Rotigotine.Approved
EtorphineEtorphine may increase the sedative activities of Rotigotine.Illicit, Vet Approved
EtravirineThe serum concentration of Rotigotine can be decreased when it is combined with Etravirine.Approved
EzogabineEzogabine may increase the sedative activities of Rotigotine.Approved
FelbamateFelbamate may increase the sedative activities of Rotigotine.Approved
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Rotigotine.Approved, Investigational
FencamfamineFencamfamine may increase the sedative activities of Rotigotine.Approved, Illicit, Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Rotigotine.Approved
FentanylFentanyl may increase the sedative activities of Rotigotine.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Rotigotine.Approved
FexofenadineFexofenadine may increase the sedative activities of Rotigotine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Rotigotine.Approved
FlibanserinFlibanserin may increase the sedative activities of Rotigotine.Approved
FluconazoleThe metabolism of Rotigotine can be decreased when combined with Fluconazole.Approved
FludiazepamFludiazepam may increase the sedative activities of Rotigotine.Approved, Illicit
FlunarizineFlunarizine may increase the sedative activities of Rotigotine.Approved
FlunitrazepamFlunitrazepam may increase the sedative activities of Rotigotine.Approved, Illicit
FluoxetineThe metabolism of Rotigotine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolFlupentixol may increase the sedative activities of Rotigotine.Approved, Withdrawn
FluphenazineFluphenazine may increase the sedative activities of Rotigotine.Approved
FlurazepamFlurazepam may increase the sedative activities of Rotigotine.Approved, Illicit
FluspirileneFluspirilene may increase the sedative activities of Rotigotine.Approved
Fluticasone PropionateFluticasone Propionate may increase the sedative activities of Rotigotine.Approved
FluvoxamineFluvoxamine may increase the sedative activities of Rotigotine.Approved, Investigational
FosamprenavirThe metabolism of Rotigotine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Rotigotine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Rotigotine.Approved
FosphenytoinFosphenytoin may increase the sedative activities of Rotigotine.Approved
FospropofolFospropofol may increase the sedative activities of Rotigotine.Approved, Illicit
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Rotigotine.Approved, Vet Approved
Fusidic AcidThe serum concentration of Rotigotine can be increased when it is combined with Fusidic Acid.Approved
GabapentinGabapentin may increase the sedative activities of Rotigotine.Approved, Investigational
gabapentin enacarbilgabapentin enacarbil may increase the sedative activities of Rotigotine.Approved
Gamma Hydroxybutyric AcidGamma Hydroxybutyric Acid may increase the sedative activities of Rotigotine.Approved, Illicit
GepironeGepirone may increase the sedative activities of Rotigotine.Investigational
GlutethimideGlutethimide may increase the sedative activities of Rotigotine.Approved, Illicit
GuanfacineGuanfacine may increase the sedative activities of Rotigotine.Approved, Investigational
HalazepamHalazepam may increase the sedative activities of Rotigotine.Approved, Illicit, Withdrawn
HaloperidolHaloperidol may increase the sedative activities of Rotigotine.Approved
HalothaneHalothane may increase the sedative activities of Rotigotine.Approved, Vet Approved
HeroinHeroin may increase the sedative activities of Rotigotine.Approved, Illicit
HexobarbitalHexobarbital may increase the sedative activities of Rotigotine.Approved
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Rotigotine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Rotigotine.Approved, Vet Approved
HydrocodoneHydrocodone may increase the sedative activities of Rotigotine.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Rotigotine.Approved
HydromorphoneHydromorphone may increase the sedative activities of Rotigotine.Approved, Illicit
HydroxyzineHydroxyzine may increase the sedative activities of Rotigotine.Approved
IdelalisibThe serum concentration of Rotigotine can be increased when it is combined with Idelalisib.Approved
IloperidoneIloperidone may increase the sedative activities of Rotigotine.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Rotigotine.Approved, Investigational
ImatinibThe metabolism of Rotigotine can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Rotigotine.Investigational
ImipramineImipramine may increase the sedative activities of Rotigotine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Rotigotine.Approved
IndinavirThe metabolism of Rotigotine can be decreased when combined with Indinavir.Approved
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Rotigotine.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Rotigotine.Approved, Investigational
IsavuconazoniumThe metabolism of Rotigotine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Rotigotine.Approved
IsofluraneIsoflurane may increase the sedative activities of Rotigotine.Approved, Vet Approved
IsoniazidThe metabolism of Rotigotine can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Rotigotine.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Rotigotine.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Rotigotine.Approved, Withdrawn
IsradipineThe metabolism of Rotigotine can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Rotigotine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Rotigotine can be increased when it is combined with Ivacaftor.Approved
KetamineKetamine may increase the sedative activities of Rotigotine.Approved, Vet Approved
KetazolamKetazolam may increase the sedative activities of Rotigotine.Approved
KetobemidoneKetobemidone may increase the sedative activities of Rotigotine.Approved
KetoconazoleThe metabolism of Rotigotine can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Rotigotine.Approved
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Rotigotine.Approved
LamotrigineLamotrigine may increase the sedative activities of Rotigotine.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Rotigotine.Approved, Investigational
LevetiracetamLevetiracetam may increase the sedative activities of Rotigotine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Rotigotine.Approved
LevobupivacaineLevobupivacaine may increase the sedative activities of Rotigotine.Approved
LevocabastineLevocabastine may increase the sedative activities of Rotigotine.Approved
LevocetirizineLevocetirizine may increase the sedative activities of Rotigotine.Approved
LevodopaLevodopa may increase the sedative activities of Rotigotine.Approved
Levomethadyl AcetateLevomethadyl Acetate may increase the sedative activities of Rotigotine.Approved
LevorphanolLevorphanol may increase the sedative activities of Rotigotine.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Rotigotine.Approved, Investigational
LidocaineLidocaine may increase the sedative activities of Rotigotine.Approved, Vet Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Rotigotine.Approved, Investigational
LithiumLithium may increase the sedative activities of Rotigotine.Approved
LofentanilLofentanil may increase the sedative activities of Rotigotine.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Rotigotine.Approved, Investigational
LopinavirThe metabolism of Rotigotine can be decreased when combined with Lopinavir.Approved
LoratadineLoratadine may increase the sedative activities of Rotigotine.Approved
LorazepamLorazepam may increase the sedative activities of Rotigotine.Approved
LorcaserinThe metabolism of Rotigotine can be decreased when combined with Lorcaserin.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Rotigotine.Approved
LovastatinThe metabolism of Rotigotine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineLoxapine may increase the sedative activities of Rotigotine.Approved
Lu AA21004Lu AA21004 may increase the sedative activities of Rotigotine.Investigational
LuliconazoleThe serum concentration of Rotigotine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Rotigotine can be increased when combined with Lumacaftor.Approved
LumateperoneThe therapeutic efficacy of Rotigotine can be decreased when used in combination with Lumateperone.Investigational
LumefantrineThe metabolism of Rotigotine can be decreased when combined with Lumefantrine.Approved
LurasidoneLurasidone may increase the sedative activities of Rotigotine.Approved
Magnesium SulfateMagnesium Sulfate may increase the sedative activities of Rotigotine.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Rotigotine.Approved, Investigational
MaprotilineMaprotiline may increase the sedative activities of Rotigotine.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Rotigotine.Approved
MeclizineMeclizine may increase the sedative activities of Rotigotine.Approved
MedetomidineMedetomidine may increase the sedative activities of Rotigotine.Vet Approved
MelatoninMelatonin may increase the sedative activities of Rotigotine.Approved, Nutraceutical, Vet Approved
MelperoneMelperone may increase the sedative activities of Rotigotine.Approved
MepivacaineMepivacaine may increase the sedative activities of Rotigotine.Approved, Vet Approved
MeprobamateMeprobamate may increase the sedative activities of Rotigotine.Approved, Illicit
MesoridazineMesoridazine may increase the sedative activities of Rotigotine.Approved
MetaxaloneMetaxalone may increase the sedative activities of Rotigotine.Approved
MethadoneMethadone may increase the sedative activities of Rotigotine.Approved
Methadyl AcetateMethadyl Acetate may increase the sedative activities of Rotigotine.Approved, Illicit
MethapyrileneMethapyrilene may increase the sedative activities of Rotigotine.Withdrawn
MethaqualoneMethaqualone may increase the sedative activities of Rotigotine.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Rotigotine.Approved
MethocarbamolMethocarbamol may increase the sedative activities of Rotigotine.Approved, Vet Approved
MethohexitalMethohexital may increase the sedative activities of Rotigotine.Approved
MethotrimeprazineMethotrimeprazine may increase the sedative activities of Rotigotine.Approved
MethoxyfluraneMethoxyflurane may increase the sedative activities of Rotigotine.Approved, Vet Approved
MethsuximideMethsuximide may increase the sedative activities of Rotigotine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Rotigotine.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Rotigotine.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Rotigotine.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the sedative activities of Rotigotine.Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Rotigotine.Approved
MetoclopramideThe therapeutic efficacy of Rotigotine can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Rotigotine.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Rotigotine.Approved, Investigational
MexiletineThe metabolism of Rotigotine can be decreased when combined with Mexiletine.Approved
MidazolamMidazolam may increase the sedative activities of Rotigotine.Approved, Illicit
MifepristoneThe serum concentration of Rotigotine can be increased when it is combined with Mifepristone.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Rotigotine.Approved
MirabegronThe metabolism of Rotigotine can be decreased when combined with Mirabegron.Approved
MirtazapineMirtazapine may increase the sedative activities of Rotigotine.Approved
MitotaneThe serum concentration of Rotigotine can be decreased when it is combined with Mitotane.Approved
ModafinilThe serum concentration of Rotigotine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Rotigotine.Approved
MolindoneMolindone may increase the sedative activities of Rotigotine.Approved
MorphineMorphine may increase the sedative activities of Rotigotine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Rotigotine.Approved
NabiloneNabilone may increase the sedative activities of Rotigotine.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Rotigotine.Approved
NafcillinThe serum concentration of Rotigotine can be decreased when it is combined with Nafcillin.Approved
NalbuphineNalbuphine may increase the sedative activities of Rotigotine.Approved
NebivololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Rotigotine.Approved, Investigational
NefazodoneThe metabolism of Rotigotine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Rotigotine can be decreased when combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Rotigotine.Approved, Investigational
NetupitantThe serum concentration of Rotigotine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Rotigotine can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Rotigotine can be decreased when combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Rotigotine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Rotigotine.Approved
NilotinibThe metabolism of Rotigotine can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Rotigotine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Rotigotine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Rotigotine.Approved
NitrazepamNitrazepam may increase the sedative activities of Rotigotine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Rotigotine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Rotigotine.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Rotigotine.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Rotigotine.Approved
Nitrous oxideNitrous oxide may increase the sedative activities of Rotigotine.Approved, Vet Approved
NormethadoneNormethadone may increase the sedative activities of Rotigotine.Approved, Illicit
NortriptylineNortriptyline may increase the sedative activities of Rotigotine.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Rotigotine.Approved
OlanzapineOlanzapine may increase the sedative activities of Rotigotine.Approved, Investigational
OlaparibThe metabolism of Rotigotine can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Rotigotine.Approved, Investigational
OlopatadineOlopatadine may increase the sedative activities of Rotigotine.Approved
OndansetronOndansetron may increase the sedative activities of Rotigotine.Approved
OpiumOpium may increase the sedative activities of Rotigotine.Approved, Illicit
OrphenadrineOrphenadrine may increase the sedative activities of Rotigotine.Approved
OsanetantOsanetant may increase the sedative activities of Rotigotine.Investigational
OsimertinibThe serum concentration of Rotigotine can be increased when it is combined with Osimertinib.Approved
OxazepamOxazepam may increase the sedative activities of Rotigotine.Approved
OxetacaineOxetacaine may increase the sedative activities of Rotigotine.Investigational
OxprenololOxprenolol may increase the sedative activities of Rotigotine.Approved
OxybuprocaineOxybuprocaine may increase the sedative activities of Rotigotine.Approved
OxycodoneOxycodone may increase the sedative activities of Rotigotine.Approved, Illicit, Investigational
OxymorphoneOxymorphone may increase the sedative activities of Rotigotine.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Rotigotine.Approved, Vet Approved
PalbociclibThe serum concentration of Rotigotine can be increased when it is combined with Palbociclib.Approved
PaliperidonePaliperidone may increase the sedative activities of Rotigotine.Approved
PanobinostatThe serum concentration of Rotigotine can be increased when it is combined with Panobinostat.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Rotigotine.Approved
ParaldehydeParaldehyde may increase the sedative activities of Rotigotine.Approved
ParoxetineThe metabolism of Rotigotine can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Rotigotine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Rotigotine.Approved, Investigational
PentazocinePentazocine may increase the sedative activities of Rotigotine.Approved, Vet Approved
PentobarbitalPentobarbital may increase the sedative activities of Rotigotine.Approved, Vet Approved
PerampanelPerampanel may increase the sedative activities of Rotigotine.Approved
PerazinePerazine may increase the sedative activities of Rotigotine.Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Rotigotine.Approved
PerospironePerospirone may increase the sedative activities of Rotigotine.Approved
PerphenazinePerphenazine may increase the sedative activities of Rotigotine.Approved
PethidinePethidine may increase the sedative activities of Rotigotine.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Rotigotine.Approved
PhenobarbitalPhenobarbital may increase the sedative activities of Rotigotine.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Rotigotine.Approved
PhenoxyethanolPhenoxyethanol may increase the sedative activities of Rotigotine.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Rotigotine.Approved
PhenytoinPhenytoin may increase the sedative activities of Rotigotine.Approved, Vet Approved
PimavanserinThe therapeutic efficacy of Rotigotine can be decreased when used in combination with Pimavanserin.Investigational
PimozidePimozide may increase the sedative activities of Rotigotine.Approved
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Rotigotine.Approved
PipamperonePipamperone may increase the sedative activities of Rotigotine.Approved
PipotiazinePipotiazine may increase the sedative activities of Rotigotine.Approved
PiritramidePiritramide may increase the sedative activities of Rotigotine.Investigational
PizotifenPizotifen may increase the sedative activities of Rotigotine.Approved
PomalidomidePomalidomide may increase the sedative activities of Rotigotine.Approved
PosaconazoleThe metabolism of Rotigotine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Rotigotine.Approved, Investigational
PramocainePramocaine may increase the sedative activities of Rotigotine.Approved
PrazepamPrazepam may increase the sedative activities of Rotigotine.Approved, Illicit
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Rotigotine.Approved
PregabalinPregabalin may increase the sedative activities of Rotigotine.Approved, Illicit, Investigational
PregnanolonePregnanolone may increase the sedative activities of Rotigotine.Investigational
PrilocainePrilocaine may increase the sedative activities of Rotigotine.Approved
PrimidonePrimidone may increase the sedative activities of Rotigotine.Approved, Vet Approved
ProcaineProcaine may increase the sedative activities of Rotigotine.Approved, Investigational, Vet Approved
ProchlorperazineProchlorperazine may increase the sedative activities of Rotigotine.Approved, Vet Approved
PromazinePromazine may increase the sedative activities of Rotigotine.Approved, Vet Approved
PromethazinePromethazine may increase the sedative activities of Rotigotine.Approved
ProparacaineProparacaine may increase the sedative activities of Rotigotine.Approved, Vet Approved
PropericiazineThe therapeutic efficacy of Propericiazine can be decreased when used in combination with Rotigotine.Approved
PropofolPropofol may increase the sedative activities of Rotigotine.Approved, Investigational, Vet Approved
PropoxycainePropoxycaine may increase the sedative activities of Rotigotine.Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Rotigotine.Approved, Investigational
ProtriptylineProtriptyline may increase the sedative activities of Rotigotine.Approved
PSD502PSD502 may increase the sedative activities of Rotigotine.Investigational
QuazepamQuazepam may increase the sedative activities of Rotigotine.Approved, Illicit
QuetiapineQuetiapine may increase the sedative activities of Rotigotine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Rotigotine.Approved, Investigational
QuinidineThe metabolism of Rotigotine can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Rotigotine can be decreased when combined with Quinine.Approved
RacloprideRaclopride may increase the sedative activities of Rotigotine.Investigational
RamelteonRamelteon may increase the sedative activities of Rotigotine.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Rotigotine.Approved
RanolazineThe metabolism of Rotigotine can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Rotigotine.Approved
RemifentanilRemifentanil may increase the sedative activities of Rotigotine.Approved
RemoxiprideRemoxipride may increase the sedative activities of Rotigotine.Approved, Withdrawn
ReserpineReserpine may increase the sedative activities of Rotigotine.Approved
RifabutinThe metabolism of Rotigotine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Rotigotine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Rotigotine can be increased when combined with Rifapentine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Riociguat is combined with Rotigotine.Approved
RisperidoneRisperidone may increase the sedative activities of Rotigotine.Approved, Investigational
RitanserinRitanserin may increase the sedative activities of Rotigotine.Investigational
RitonavirThe metabolism of Rotigotine can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Rotigotine can be decreased when combined with Rolapitant.Approved
RomifidineRomifidine may increase the sedative activities of Rotigotine.Vet Approved
RopiniroleThe metabolism of Rotigotine can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineRopivacaine may increase the sedative activities of Rotigotine.Approved
RP5063The therapeutic efficacy of Rotigotine can be decreased when used in combination with RP5063.Investigational
S-EthylisothioureaS-Ethylisothiourea may increase the sedative activities of Rotigotine.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Rotigotine is combined with Sacubitril.Approved
Sage 547Sage 547 may increase the sedative activities of Rotigotine.Investigational
SaquinavirThe metabolism of Rotigotine can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineScopolamine may increase the sedative activities of Rotigotine.Approved
SecobarbitalSecobarbital may increase the sedative activities of Rotigotine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Selegiline.Approved, Investigational, Vet Approved
SertindoleSertindole may increase the sedative activities of Rotigotine.Approved, Withdrawn
SertralineThe metabolism of Rotigotine can be decreased when combined with Sertraline.Approved
SevofluraneSevoflurane may increase the sedative activities of Rotigotine.Approved, Vet Approved
SildenafilThe metabolism of Rotigotine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Rotigotine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Rotigotine can be increased when it is combined with Simeprevir.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Rotigotine is combined with Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the sedative activities of Rotigotine.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Rotigotine.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Rotigotine.Approved
St. John's WortThe serum concentration of Rotigotine can be decreased when it is combined with St. John&#39;s Wort.Nutraceutical
StiripentolThe serum concentration of Rotigotine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Rotigotine is combined with Streptokinase.Approved
SufentanilSufentanil may increase the sedative activities of Rotigotine.Approved, Investigational
SulfisoxazoleThe metabolism of Rotigotine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideSulpiride may increase the sedative activities of Rotigotine.Approved
SuvorexantSuvorexant may increase the sedative activities of Rotigotine.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Rotigotine is combined with Tamsulosin.Approved, Investigational
TandospironeTandospirone may increase the sedative activities of Rotigotine.Investigational
TapentadolTapentadol may increase the sedative activities of Rotigotine.Approved
TasimelteonTasimelteon may increase the sedative activities of Rotigotine.Approved
TelaprevirThe metabolism of Rotigotine can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Rotigotine can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Rotigotine.Approved, Investigational
TemazepamTemazepam may increase the sedative activities of Rotigotine.Approved
TenofovirThe metabolism of Rotigotine can be decreased when combined with Tenofovir.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Rotigotine.Approved
TerbinafineThe metabolism of Rotigotine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TeriflunomideThe serum concentration of Rotigotine can be decreased when it is combined with Teriflunomide.Approved
TetrabenazineTetrabenazine may increase the sedative activities of Rotigotine.Approved
TetracaineTetracaine may increase the sedative activities of Rotigotine.Approved, Vet Approved
TetrodotoxinTetrodotoxin may increase the sedative activities of Rotigotine.Investigational
ThalidomideThalidomide may increase the sedative activities of Rotigotine.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Rotigotine can be decreased when combined with Theophylline.Approved
ThiamylalThiamylal may increase the sedative activities of Rotigotine.Approved, Vet Approved
ThiopentalThiopental may increase the sedative activities of Rotigotine.Approved, Vet Approved
ThioproperazineThe therapeutic efficacy of Thioproperazine can be decreased when used in combination with Rotigotine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Rotigotine.Approved
ThiothixeneThiothixene may increase the sedative activities of Rotigotine.Approved
TiagabineTiagabine may increase the sedative activities of Rotigotine.Approved
TiaprideTiapride may increase the sedative activities of Rotigotine.Investigational
TiclopidineThe metabolism of Rotigotine can be decreased when combined with Ticlopidine.Approved
TiletamineTiletamine may increase the sedative activities of Rotigotine.Vet Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Rotigotine.Approved
TipranavirThe metabolism of Rotigotine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the sedative activities of Rotigotine.Approved
TocilizumabThe serum concentration of Rotigotine can be decreased when it is combined with Tocilizumab.Approved
TolazolineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Tolazoline.Approved, Vet Approved
TolcaponeTolcapone may increase the sedative activities of Rotigotine.Approved, Withdrawn
TopiramateTopiramate may increase the sedative activities of Rotigotine.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Rotigotine.Approved
TramadolTramadol may increase the sedative activities of Rotigotine.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Rotigotine.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the sedative activities of Rotigotine.Experimental
TranylcypromineTranylcypromine may increase the sedative activities of Rotigotine.Approved
TrazodoneTrazodone may increase the sedative activities of Rotigotine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Rotigotine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Rotigotine.Approved
TriazolamTriazolam may increase the sedative activities of Rotigotine.Approved
TrifluoperazineTrifluoperazine may increase the sedative activities of Rotigotine.Approved
TriflupromazineTriflupromazine may increase the sedative activities of Rotigotine.Approved, Vet Approved
TrimipramineTrimipramine may increase the sedative activities of Rotigotine.Approved
TriprolidineTriprolidine may increase the sedative activities of Rotigotine.Approved
Uc1010Uc1010 may increase the sedative activities of Rotigotine.Investigational
Valproic AcidValproic Acid may increase the sedative activities of Rotigotine.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Rotigotine.Approved, Investigational
VemurafenibThe serum concentration of Rotigotine can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Rotigotine can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Rotigotine can be decreased when combined with Verapamil.Approved
VigabatrinVigabatrin may increase the sedative activities of Rotigotine.Approved
VoriconazoleThe metabolism of Rotigotine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineVortioxetine may increase the sedative activities of Rotigotine.Approved
XylazineXylazine may increase the sedative activities of Rotigotine.Vet Approved
ZaleplonZaleplon may increase the sedative activities of Rotigotine.Approved, Illicit, Investigational
ZiconotideZiconotide may increase the sedative activities of Rotigotine.Approved
ZiprasidoneZiprasidone may increase the sedative activities of Rotigotine.Approved
ZolazepamZolazepam may increase the sedative activities of Rotigotine.Vet Approved
ZolpidemZolpidem may increase the sedative activities of Rotigotine.Approved
ZonisamideZonisamide may increase the sedative activities of Rotigotine.Approved, Investigational
ZopicloneZopiclone may increase the sedative activities of Rotigotine.Approved
ZotepineZotepine may increase the sedative activities of Rotigotine.Approved
ZuclopenthixolZuclopenthixol may increase the sedative activities of Rotigotine.Approved, Investigational
Food Interactions
  • Because rotigotine is administered transdermally, food should not affect absorption, and the product may be administered without regard to the timing of meals.
References
Synthesis Reference

Hans-Michael Wolff, Luc Quere, Jens Riedner, “NOVEL POLYMORPHIC FORM OF ROTIGOTINE AND PROCESS FOR PRODUCTION.” U.S. Patent US20090143460, issued June 04, 2009.

US20090143460
General References
  1. Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH: Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord. 2007 Dec;22(16):2398-404. [PubMed:17935234 ]
  2. Chen JJ, Swope DM, Dashtipour K, Lyons KE: Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease. Pharmacotherapy. 2009 Dec;29(12):1452-67. doi: 10.1592/phco.29.12.1452. [PubMed:19947805 ]
  3. Perez-Lloret S, Rey MV, Ratti PL, Rascol O: Rotigotine transdermal patch for the treatment of Parkinson's Disease. Fundam Clin Pharmacol. 2013 Feb;27(1):81-95. doi: 10.1111/j.1472-8206.2012.01028.x. Epub 2012 Feb 9. [PubMed:22320451 ]
  4. de Biase S, Merlino G, Lorenzut S, Valente M, Gigli GL: ADMET considerations for restless leg syndrome drug treatments. Expert Opin Drug Metab Toxicol. 2012 Oct;8(10):1247-61. doi: 10.1517/17425255.2012.708023. Epub 2012 Jul 18. [PubMed:22808933 ]
External Links
ATC CodesN04BC09
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (1.34 MB)
MSDSDownload (29.9 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9968
Blood Brain Barrier+0.9808
Caco-2 permeable+0.5864
P-glycoprotein substrateSubstrate0.7351
P-glycoprotein inhibitor INon-inhibitor0.6945
P-glycoprotein inhibitor IIInhibitor0.6398
Renal organic cation transporterInhibitor0.6722
CYP450 2C9 substrateNon-substrate0.5674
CYP450 2D6 substrateNon-substrate0.5502
CYP450 3A4 substrateSubstrate0.5937
CYP450 1A2 substrateInhibitor0.724
CYP450 2C9 inhibitorNon-inhibitor0.7855
CYP450 2D6 inhibitorInhibitor0.8238
CYP450 2C19 inhibitorNon-inhibitor0.7351
CYP450 3A4 inhibitorInhibitor0.5691
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8638
Ames testNon AMES toxic0.5
CarcinogenicityNon-carcinogens0.9255
BiodegradationNot ready biodegradable0.9912
Rat acute toxicity2.6229 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6074
hERG inhibition (predictor II)Inhibitor0.7098
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Kit
PatchTransdermal1 mg
PatchTransdermal2 mg
PatchTransdermal3 mg
PatchTransdermal4 mg
PatchTransdermal6 mg
PatchTransdermal8 mg
Patch, extended releaseTransdermal1 mg/24h
Patch, extended releaseTransdermal2 mg/24h
Patch, extended releaseTransdermal3 mg/24h
Patch, extended releaseTransdermal4 mg/24h
Patch, extended releaseTransdermal6 mg/24h
Patch, extended releaseTransdermal8 mg/24h
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6699498 No2000-11-272020-11-27Us
US6884434 No2001-03-302021-03-30Us
US7413747 No1999-03-182019-03-18Us
US8246979 No2007-09-012027-09-01Us
US8246980 No2005-11-272025-11-27Us
US8617591 No2003-07-222023-07-22Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP4.70BIOBYTE STARLIST (2009)
Predicted Properties
PropertyValueSource
Water Solubility0.00904 mg/mLALOGPS
logP5.01ALOGPS
logP4.34ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)10.03ChemAxon
pKa (Strongest Basic)10.97ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area23.47 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity94.56 m3·mol-1ChemAxon
Polarizability36.56 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as tetralins. These are polycyclic aromatic compounds containing a tetralin moiety, which consists of a benzene fused to a cyclohexane.
KingdomOrganic compounds
Super ClassBenzenoids
ClassTetralins
Sub ClassNot Available
Direct ParentTetralins
Alternative Parents
Substituents
  • Tetralin
  • Phenol
  • 1-hydroxy-4-unsubstituted benzenoid
  • 1-hydroxy-2-unsubstituted benzenoid
  • Aralkylamine
  • Thiophene
  • Heteroaromatic compound
  • Tertiary amine
  • Tertiary aliphatic amine
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organic oxygen compound
  • Amine
  • Organic nitrogen compound
  • Organooxygen compound
  • Organonitrogen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Sh3 domain binding
Specific Function:
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).
Gene Name:
DRD4
Uniprot ID:
P21917
Molecular Weight:
48359.86 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD5
Uniprot ID:
P21918
Molecular Weight:
52950.5 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  2. Scheller D, Ullmer C, Berkels R, Gwarek M, Lubbert H: The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):73-86. doi: 10.1007/s00210-008-0341-4. Epub 2008 Aug 14. [PubMed:18704368 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Scheller D, Ullmer C, Berkels R, Gwarek M, Lubbert H: The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):73-86. doi: 10.1007/s00210-008-0341-4. Epub 2008 Aug 14. [PubMed:18704368 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
Comments
comments powered by Disqus
Drug created on November 18, 2007 11:23 / Updated on December 07, 2016 02:38